Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on April 06, 2018, 11:03:41 am
-
Twelve weeks of Merck’s Zepatier (grazoprevir/elbasvir) plus Gilead Sciences’ Sovaldi (sofosbuvir) cures hepatitis C virus (HCV) at a very high rate among those with cirrhosis and genotype 3 of the virus. This holds true regardless of any mutations their virus may have that are associated with resistance to treatment.
Publishing their findings in the journal Hepatology, researchers from the randomized open-label Phase II C-ISLE study gave 12 or 16 weeks of Sovaldi plus Zepatier, with or without ribavirin, to a group of people with genotype 3 of hep C and compensated cirrhosis (the milder form of the advanced liver disease).
Read more...
https://www.hepmag.com/article/zepatier-plus-sovaldi-works-cirrhotic-people-genotype-3-hep-c